Illumina shareholders who failed to overthrow the company's leadership a month ago may get what they want after all.
Francis deSouza resigned as the genetic sequencing company’s CEO and chairman on 11 June. He had served as chairman since...
CEO Resignation Raises Doubts About Illumina’s Commitment To Grail
Listen to this article
Francis deSouza resigned as CEO and chairman of Illumina just a few weeks after winning the support of shareholders. General counsel Charles Dadswell will take over as interim CEO.
Keep up with the top medtech business and regulatory news.
More from Leadership
• By
This week, the FDA announced a new head of its device evaluation office; synthetic genomics firm Constructive Bio landed $58m in funding; and Natera got a permanent injuction against NeoGenomics Labs' RaDaR assay.
Tim Schmid, executive VP and worldwide chairman of J&J MedTech, expects Shockwave, acquired in April, and Abiomed, purchased in late 2022, to be “long-term gems” for the company. Cardiovascular is among higher-growth segments where J&J has concentrated investments in recent years, along with robotic surgical systems.
• By
The US FDA has published a trio of draft guidance documents for its Assessment Scheme for Conformity Program, which began as a pilot in September 2020 to capitalize on the role of standards in the regulation of medical devices.
• By
Inari Medical is updating use instructions for a clot-removing catheter due to the potential for serious adverse effects, including death.
More from Medtech Insight
• By
AdvaMed president Scott Whitaker said the group is focused on the need for tariff stability in conversations with the Trump administration. The organization remains optimistic about other policy areas. New chairman and ResMed CEO Mick Farrell laid out his five priorities.
• By
Class III devices and panel-track supplements approved by US FDA’s Center for Devices and Radiological Health. Data derived from FDA.gov. Updated weekly.
• By
AdvaMed president Scott Whitaker said the group is focused on the need for tariff stability in conversations with the Trump administration. The organization remains optimistic about other policy areas. New chairman and ResMed CEO Mick Farrell laid out his five priorities.